

Disclaimer:

The clinical trial data presented on this website is compiled from publicly available sources, including the Clinical Trials Registry – India (CTRI) <https://ctri.nic.in/>. Lung Connect India Foundation does not claim ownership of the original data and does not independently verify its accuracy, completeness, or timeliness.

This information is provided solely for educational and informational purposes and should not be considered as medical advice or a substitute for professional consultation. We strongly encourage patients and healthcare professionals to refer to the original sources and consult relevant authorities before making any healthcare decisions.

Lung Connect India Foundation assumes no liability for any errors, omissions, or actions taken based on this data. If you believe any information requires correction, please refer to the official CTRI website or contact the respective clinical trial sponsors.

CTRI No.	Public Title	Type of Trial	Recruitment Status	Health Condition	Basic Inclusion criteria (Click on View for more detail of criteria)	Intervention/Drug/Treatment Name	Location	Details of Trails
CTRI/2011/08/001942	A Study in Second Line Non Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Non Small Cell Lung Cancer	Disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy Stage IV Non-Small Cell Lung Cancer	Docetaxel + Ramucirumab	A.H. Regional Cancer Centre,ORISSA Bhagwan Mahaveer Cancer Hospital and Research Centre,RAJASTHAN Jaslok Hospital and Research Centre,MAHARASHTRA Jehangir Hospital,MAHARASHTRA Lakeshore Hospital and Research Center,KERALA Madurai Medical College and Government Rajaji Hospital,TAMIL NADU Narayana Hrudayalaya Institute of Medicine,KARNATAKA Rajiv Gandhi Cancer Institute and Research Center,DELHI Regional Cancer Centre,KERALA Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2011/11/002104	This is a comparative study for the Etoposide 50 mg capsules manufactured with Mylan Inc. USA, in patients with small cell lung cancers under fasting condition.	BA/BE	Indian: Open to Recruitment	Cancer Patients (Small Cell Lung Cancer)	Patients already receiving etoposide and expected to receive at least two additional cycles at the same dose.	Etoposide 50 mg capsules	Central India Cancer Research Institute,MAHARASHTRA Jeevandeep Oncosurgical Hospital,GUJARAT Kailash Cancer Hospital and Research Centre,GUJARAT Life Research Centre,GUJARAT Mahavir Cancer Sansthan,BIHAR NRR Hospital,KARNATAKA Suyash Hospital,MADHYA PRADESH Vintage Hospital and Research Centre,GOA	View
CTRI/2012/02/002410	A Phase 2b study with study drug and carboplatin and paclitaxel for Subjects with Advanced Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Patients with advanced non-small cell lung cancer	Subjects must have either stage IIIB with pleural effusion or IV NSCLC with radiographically measurable disease (RECIST 1.1 criteria). Women non-smokers with stage IV NSCLC should be screened for EGFR mutation and if positive be excluded from the study and placed on an EGFR kinase inhibitor.	Tamibarotene Plus Paclitaxel and Carboplatin	Curie Manavta Cancer Centre,MAHARASHTRA Dr Kamakshi Memorial Hospital,TAMIL NADU G Kuppuswamy Naidu Memorial Hospital,TAMIL NADU M S Patel Cancer Centre, Shree Krishna Hospital,GUJARAT NIZAMS Institute of Medical Sciences,ANDHRA PRADESH Noble Hospital,MAHARASHTRA Orchid Nursing Home,WEST BENGAL Shatabdi Super Speciality Hospital,MAHARASHTRA	View
CTRI/2012/09/002972	To compare the blood levels of Pemetrexed in Non small cell lung cancer patients treated with Alimta and Pemgem	BA/BE	Indian: Open to Recruitment	Indian adult ChemoNaive Adenocarcinoma Non-small cell lung cancer patient	Patients with a histologic or cytologic diagnosis of Adenocarcinoma - NSCLC Stage IIIA, IIIB, or IV not amenable to curative treatment surgery or radiotherapy	PEMGEM (Dr. Reddys Lab) 500 mg/m ² IV over 10 minute	ACTREC Tata memorial centre,MAHARASHTRA	View
CTRI/2014/09/005042	A Phase III study to compare the safety and efficacy of Bevacizumab against Avastin,4 in Patients with Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer	Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer,	Bevacizumab_Intas	Acharya Harihar Regional Cancer Centre,ORISSA All India Institute of Medical Sciences,DELHI Amrita Institute of Medical Sciences,KERALA Apple Hospital,GUJARAT B. J. Govt. Medical College & Sassoon General Hospital,MAHARASHTRA Batra Hospital & Medical Research Centre,DELHI BGS Global Hospitals,KARNATAKA BIBI General Hospital and Cancer Centre,ANDHRA PRADESH City Cancer Centre,ANDHRA PRADESH Curie Manavata Cancer Centre,MAHARASHTRA Dr. Kamakshi Memorial Hospital Pvt. Ltd.,TAMIL NADU Dr. Rai Memorial Medical Centre,TAMIL NADU HCG Bangalore Institute of Oncology,KARNATAKA	View

							<p>HCG Cancer centre,GUJARAT</p> <p>Health Point Multispecialty Hospital,WEST BENGAL</p> <p>IPGMR and SSKM Hospital,WEST BENGAL</p> <p>King George Medical University (Erstwhile CSMMU),UTTAR PRADESH</p> <p>Life Care Hospital,KARNATAKA</p> <p>Netaji Subhash Chandra Bose Cancer Research Institute,WEST BENGAL</p> <p>Post Graduate Institute of Medical Education & Research,CHANDIGARH</p> <p>Prince Aly Khan Hospital,MAHARASHTRA</p> <p>Rajiv Gandhi Cancer Institute and Research Centre,DELHI</p> <p>Rajiv Gandhi Government General Hospital & Madras Medical College,TAMIL NADU</p> <p>Regional Cancer Centre, Medical College Campus,KERALA</p> <p>S.S. Hospital and Research Centre,BIHAR</p> <p>Sparsh Hospitals & Critical Care Pvt. Ltd.,ORISSA</p> <p>Srinivasam Cancer Care Hospitals India Pvt. Ltd.,KARNATAKA</p> <p>Unique Hospital Multispecialty & Research Institute,GUJARAT</p>	
CTRI/2015/01/005348	Exercise for the management of the cancer-related fatigue in advanced lung cancer.	Interventional	Indian: Open to Recruitment	Diagnosis of advanced lung cancer (stage III&IV NSCLC), declared as unresectable by the multidisciplinary oncology team.	Diagnosis of advanced lung cancer (stage III&IV NSCLC), declared as unresectable by the multidisciplinary oncology team	Mixed exercises, which includes resistance exercises and aerobic exercises.	Physiotherapy Department, Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2017/09/009954	A study to understand if different brands of the drugs Erlotinib or Gefitinib used in lung cancer give the same concentration in blood of patients and whether they can be used interchangeably.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of main bronchus	1. Patients on erlotinib/gefitinib for advanced/metastatic non-squamous NSCLC 2. Patient should have received chemotherapy with taxanes or pemetrexed with platinum	Erlotinib - Tarceva Gefitinib- Iressa	ACTREC, Tata Memorial Centre ,MAHARASHTRA	View
CTRI/2017/04/008305	A study to Assess the Safety and Efficacy of Docetaxel Lipid Suspension (DLS) for Injection of Intas Pharmaceuticals Limited, India in Lung Cancer patients.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Patient with histologically/cytologically confirmed locally advanced or metastatic NSCLC after platinum therapy failure	DOCEAQUALIP 20/80 (DOCETAXEL LIPID SUSPENSION FOR INJECTION) 20/80 mg/vial of Intas Pharmaceuticals Limited, India	<p>Apollo Hospital,ANDHRA PRADESH</p> <p>Apollo Specialty Hospital,TAMIL NADU</p> <p>Apple Hospital,GUJARAT</p> <p>City Cancer Centre,ANDHRA PRADESH</p> <p>Dinanath Mangeshkar HospitalA ,MAHARASHTRA</p> <p>Government Medical College and Hospital,MAHARASHTRA</p> <p>Gujarat Cancer & Research Institute,GUJARAT</p> <p>HCG Hospital,KARNATAKA</p> <p>HCG manavata cancer center,MAHARASHTRA</p> <p>Medica Superspecialty Hospital,WEST BENGAL</p> <p>Postgraduate Institute of Medical Education and Research,CHANDIGARH</p> <p>Shatabdi Hospital ,MAHARASHTRA</p> <p>Sir Ganga Ram Hospital,DELHI</p> <p>SMS medical college and hospital,RAJASTHAN</p> <p>Sparsh Hospital,ORISSA</p> <p>Srinivasam Cancer Care Hospitals,KARNATAKA</p> <p>Unique Hospital Multi Specialty and Research Institute ,GUJARAT</p> <p>Vedanta Institute of Medical Sciences, Hematology Oncology ClinicA ,GUJARAT</p>	View
CTRI/2017/05/008691	A Study effect of Aprepitant(Medicine) on cough in patients of lung cancer	Interventional	Indian: Open to Recruitment	Lung cancer patients having chronic cough more than 2 weeks, on cough suppressant as per treating physician choice	Lung cancer patients having chronic cough more than 2 weeks, on cough suppressant as per treating physician choice,	Aprepitant	Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2019/02/017798	Study of treatment with Durvalumab or Placebo in patients with locally advanced and surgically non-removable Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed after platinum-based chemotherapy and radiation	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	No progression following definitive, platinum-based, concurrent or sequential chemoradiation therap	Durvalumab	<p>Apollo Specialty Hospital,TAMIL NADU</p> <p>Manibhai Shivabhai Patel Cancer Centre,GUJARAT</p> <p>Shatabdi Hospital ,MAHARASHTRA</p> <p>Shettys Hospital ,KARNATAKA</p> <p>Shree Himalaya Cancer hospital and Research Institute,GUJARAT</p>	View

							Sri Venkateshwara Hospital ,KARNATAKA	
							Tata Medical Centre,WEST BENGAL	
							V. S. Hospital,TAMIL NADU	
CTRI/2019/09/021090	A Phase III Trial to Compare the Effectiveness, Safety and action of HD204 (study drug) in comparison to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (cancer of the lungs)	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	Historically confirmed metastatic Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC) that is no longer amenable to curative surgery or local therapy. Tumors without EGFR mutation or ALK receptor alteration. Patients with unknown mutation status or known EGFR mutation or ALK receptor alteration may be included provided the corresponding targeted agent is not available and chemotherapy is the standard of care of the study center.	Arm A HD204 (Bevacizumab-biosimilar) Arm B EU-Avastin® (Bevacizumab)	Bhakti Vedanta Hospital and Research Institute,MAHARASHTRA Deenanath Mangeshkar Hospital & Research Centre,MAHARASHTRA HCG Manavata Cancer Centre,MAHARASHTRA Hemato Oncology Clinic Ahmedabad Pvt Ltd, (Vedanta instituta, of medical sciences),GUJARAT Medica Super Speciality,WEST BENGAL Nirmal Hospital Private Limited,GUJARAT Noble Hospital Pvt. Ltd,MAHARASHTRA S7 Clinical Research Centre Pvt.Ltd,MAHARASHTRA Sujan Surgical Cancer Hospital & Amravati Cancer Foundation,MAHARASHTRA	View
CTRI/2019/08/020845	A study to check the efficacy of Osimertinib when given with Savolitinib in Patients with Lung Cancer who have progressed after Treatment with Osimertinib	Interventional	Indian: Open to Recruitment	Malignant neoplasm of bronchus or lung	EGFRm positive and MET positive Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib The SAVANNAH Study	Osimertinib	Apollo Speciality Hospital, Chennai,TAMIL NADU Cytecare Cancer Hospital,KARNATAKA Rajiv Gandhi Cancer Institute,DELHI Tata Medical Centre,WEST BENGAL	View
CTRI/2019/11/021872	Addition of consolidative radiation therapy to TKI versus TKI alone in driver mutated lung cancer patients	Interventional	Indian: Open to Recruitment	Malignant neoplasm of bronchus or lung	1)Patients with positive oncogene driver mutation (EGFR or ALK/ROS) 2) Patients who have received at least 2-4 months of TKI therapy without progression	Local Consolidative Radiation therapy plus TKI	Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2020/01/022617	Improving Performance status of Advanced lung cancer patients with Chemotherapy	Interventional	Indian: Open to Recruitment	Malignant neoplasm of bronchus or lung	Cytologically/pathologically confirmed NSCLC either stage 4 disease or those stage IIIC not amenable to definitive chemoradiation	Part 1: weekly paclitaxel, best supportive care Part 2 (for eligible patients): paclitaxel and carboplatin, best supportive care	All India Institute of Medical Sciences ,DELHI	View
CTRI/2020/03/023770	To Compare Carboplatin/ Paclitaxel with Cisplatin/ Etoposide in advanced Non Small Cell Lung cancer (NSCLC).	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	Stage III (IIIA/ IIIB/ IIIC) NSCLC, staged	Cisplatin and Etoposide with Radiotherapy	Dr.Akhil Kapoor,UTTAR PRADESH Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2020/04/024761	Additional Consolidated radiation therapy after chemotherapy in limited metastatic lung cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of overlapping sites of bronchus and lung	1) Patients who have received standard duration of systemic therapy (4 - 6 cycles) without progression of disease 2) Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes	Local Consolidative Radiation therapy Standard Maintenance therapy	Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2020/07/026870	A double-blind and placebo controlled clinical study conducted on patients with stage III or IVa Non-Small Cell Lung Cancer of investigational drug, CA170 in combination with Chemotherapy and Radiation Therapy at several clinical sites across India.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1. Histologically confirmed unresectable (Stage III or IVa) Non-Squamous NSCLC 2. Newly diagnosed	CA-170	All India Institute of Medical Sciences, New Delhi,DELHI Basavarakam Indo American Cancer Hospital & Research Institute,TELANGANA Grant Medical Foundation Ruby Hall Clinic,MAHARASHTRA HCG Cancer Centre,KARNATAKA HCG NMR Curie Centre of Oncology,KARNATAKA Health Care Global Enterprises Limited,KARNATAKA KLES Dr. Prabhakar Kore Hospital and MRC,KARNATAKA KR Hospital,KARNATAKA Life line Diagnostic Centre cum Nursing Home,WEST BENGAL Shetty&S Hospital,KARNATAKA Tata Medical Center, Kolkata,WEST BENGAL Tata Memorial Hospital, Mumbai,MAHARASHTRA	View
CTRI/2020/09/027575	Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Progressed on one or two prior lines of systemic therapy for advanced/metastatic disease (stage IIIB/IIIC [not candidates for surgery, radiation or multi modality therapy] or IV NSCLC) and must be candidates for single agent chemotherapy (docetaxel)	Capmatinib (INC280) 150 mg or 200 mg	Christian Medical College, TAMIL NADU Indraprastha Apollo Hospital, DELHI Noble Hospital Clinical Research Department,MAHARASHTRA	View
CTRI/2020/08/027279	Role of upfront cranial radiotherapy in asymptomatic patients of brain metastases in lung cancer with positive mutations	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Patients with positive oncogene mutation status (EGFR/ALK) Patients with radiologically confirmed parenchymal brain metastases Patients with asymptomatic Synchronous or Metachronous brain metastases	TKI alone	Tata Memorial Hospital,MAHARASHTRA	View

CTRI/2021/02/031568	COMPARISON EFFECT OF PANCHGAVYA GHRITA AND SWARASA IN LUNG CANCER	Interventional	Indian: Open to Recruitment	Other specified respiratory disorders	Diagnosed patients of Lungs Cancer, Aiveoli cancer as per Radiology	Panchgavya Swarasa	SHREE RMD AYURVED COLLEGE AND HOSPITAL,GUJARAT	View
CTRI/2021/01/030611	Study of Durvalumab or Placebo in Patients with Non-small Cell Lung Cancer (Stage II-III) whoâ€™s has residual disease after surgery and chemotherapy.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Histologically confirmed NSCLC with resectable stage II-III disease (according to IASLC Staging Manual in Thoracic Oncology v8.0) who have undergone curative intent therapy (complete resection of the primary tumor Â± neoadjuvant and/or adjuvant therapy) per SoC. Select stage IIIB (ie, T3N2 or T4N2) patients will be eligible, provided they are upstaged to T3N2 or T4N2 based on confirmed pathology after surgery. Patients who are staged as T3N2 or T4N2 prior to surgery are not eligible.	Durvalumab	ACI Cumballa Hill Hospital,MAHARASHTRA All India Institute of Medical Sciences, Delhi ,DELHI Fortis Hospital Ltd, Bannerghatta Road,KARNATAKA HCG Manavata Cancer Centre,MAHARASHTRA HealthCare Global Enterprises Ltd ,KARNATAKA Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute,MAHARASHTRA Max Super Specialty Hospital, Mohali,CHANDIGARH Max Super Specialty Hospital, Shalimar Bagh,DELHI Mazumdar Shaw Medical Center (A unit of Narayana Health),KARNATAKA Rajiv Gandhi Cancer Institute and Research Centre,DELHI Sir Ganga Ram Hospital,DELHI Tata Memorial Hospital, Mumbai,MAHARASHTRA	View
CTRI/2021/04/032961	Study of Neoadjuvant Osimertinib for the treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II, IIIB N2) disease (according to Version 8 of the IASLC Cancer Staging Manual) 6 Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialised in oncologic procedures).	Osimertinib (TAGRISSO, 4) monotherapy	All India Institute of Medical Sciences, AIIMS,DELHI Kasturba Medical College and Hospital,KARNATAKA Mahamana Pandit Madan Mohan Malaviya Cancer Centre (NPMCC),UTTAR PRADESH Rajiv Gandhi Cancer Institute and Research Centre,DELHI Tata Medical Centre, Kolkata,WEST BENGAL Tata Memorial Hospital, Mumbai,MAHARASHTRA Thangam Hospital & Thangam Cancer Center,,TAMIL NADU	View
CTRI/2021/10/037699	A Phase IIb/III clinical trial to assess the safety and efficacy of study drug, CA-170 in combination with standard chemotherapy in stage IV lung cancer patients.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	Histologically documented, treatment-naïve Stage IV NonSquamous NSCLC (Version 8 of the International Association for the Study of Lung Cancer (IASLC) Staging Manual in Thoracic Oncology (Appendix E)	CA-170	7 Orange Hospital,MAHARASHTRA Abhishek Hospital,RAJASTHAN Acharya Vinoba Bhawe Rural Hospital,MAHARASHTRA AIIMS,DELHI AIIMS Nagpur,MAHARASHTRA Amala Institute of Medical Sciences,KERALA American Oncology Institute,JAMMU & KASHMIR Amrita Institute of Medical Sciences ,KERALA Apex Wellness Hospital ,MAHARASHTRA Asian Institute of Medical Sciences,HARYANA B P Poddar Hospital & Medical Research Ltd,WEST BENGAL Basavatarakam Indo American Cancer Hospital & Research Institute,TELANGANA Binayak Multi-specialty Hospital,WEST BENGAL Cancure Health Care LLP,MAHARASHTRA Care Hospital,TELANGANA Chandan Hospital,UTTAR PRADESH Charnock Hospital,WEST BENGAL Deenanath Mangeshkar Hospital and Research Centre,MAHARASHTRA Department of Radiotherapy, NII Ratan Sircar Medical College and Hospital ,WEST BENGAL Dept of Medical Oncology, SMS Hospital,RAJASTHAN Dharamshila Narayana Superspecialty Hospital,DELHI Dr. B.L. Kapur Memorial Hospital,DELHI Erode Cancer Centre,TAMIL NADU	View

Fortis Hospital Limited,UTTAR PRADESH
Fortis Hospital Shalimar Bagh,DELHI
Fortis Hospitals limited ,MAHARASHTRA
Fortis Hospitals limited Faridabad,HARYANA
Global Hospital & Research Institute,MAHARASHTRA
GMC Srinagar Super Speciality Hospital,JAMMU & KASHMIR
Grant Medical Foundation Ruby Hall Clinic,MAHARASHTRA
Gujarat Hospital &C Gastro and Vascular Centre,GUJARAT
HCC Multispeciality Hospital LLP,GUJARAT
HCG Cancer Centre,KARNATAKA
HCG Cancer Centre,KARNATAKA
HCG City Cancer Centre,ANDHRA PRADESH
HCG Manavata Cancer Centre,MAHARASHTRA
HCG NMR Cancer Centre ,KARNATAKA
Himalayan Institute of Medical Science, Swami Rama Himalayan University,UTTARANCHAL
IMS and SUM Hospital,ORISSA
Jahangir Clinical Development Centre Private Ltd,MAHARASHTRA
K R Hospital , Mysore Medical College & Research Institute and Associated Hospitals, KARNATAKA
Kallash Cancer Hospital and Research Center ,GUJARAT
KGMU,UTTAR PRADESH
Kims Kingsway Hospitals,MAHARASHTRA
Kiran Hospital Multi Super Speciality Hospital and Research Center, GUJARAT
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, KARNATAKA
Kolhapur Cancer Centre,MAHARASHTRA
Krupamayi Hospital,MAHARASHTRA
Lifeline Diagnostics Centre cum Nursing Home,WEST BENGAL
Mahatma Gandhi Cancer Hospital and Research Institute,ANDHRA PRADESH
Malabar Cancer Centre,KERALA
Medisquare Hospital & Research Institute,GUJARAT
Meenakshi Mission Hospital and Research Centre,TAMIL NADU
MNJ Institute of Oncology & Regional Cancer Centre,TELANGANA
Netaji Subhash Chandra Bose Hospital,WEST BENGAL
Omega Hospital ,KARNATAKA
Omega Hospitals,ANDHRA PRADESH
Oncoville Cancer Hospital and Research Centre,KARNATAKA
Pandit Bhagwat Dayal Sharma Post Gradute Institute of Medical Sciences,HARYANA
PDEAs Ayurved Rughalaya and Sterling Multi-speciality Hospital MAHARASHTRA
Punjab Cancer Care Multispeciality Hospital,PUNJAB
Regency Hospital Ltd,UTTAR PRADESH
Royapettah Government Hospital, Chennai,TAMIL NADU
RST Cancer Hospital and Research Centre,MAHARASHTRA
Saikrupa Hospital,MAHARASHTRA
Sanjeevani CBCC USA Cancer Hospital,CHHATTISGARH
Sankalp Speciality Hospital,MAHARASHTRA
Sapthagiri Institute of Medical Sciences and Research Centre,KARNATAKA

						Shailya Hospital,GUJARAT Sher -I- Kashmir Institute of Medical Sciences,JAMMU & KASHMIR SP Medical College & AG of Hospitals,RAJASTHAN Sparsh Hospital and Critical care,ORISSA Sujan Surgicals Cancer Hospital,MAHARASHTRA Taran Onco Care,MADHYA PRADESH Tata Memorial Centre,MAHARASHTRA Tirunelveli Medical college and Hospital,TAMIL NADU Unique Hospital,GUJARAT Valentis Cancer Care Hospital Pvt. Ltd.,UTTAR PRADESH Vydehi Institute of Medical Sciences and Research Centre,KARNATAKA		
CTRI/2021/10/037247	Phase III Global Study to Assess the Efficacy and Safety of Bevacizumab compared to Avastin in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with Stage IIIB/IV Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower lobe,bronchus or lung	1) Subjects with histologic or cytologic diagnosis of nsNSCLC with negative or unknown sensitizing epidermal growth factor receptor mutation and documented negative or unknown anaplastic lymphoma kinase translocation 2) .Subjects with newly diagnosed or recurrent Stage IIIB or IV ns NSCLC	BP01 (Bevacizumab)	Apex well ness Hospital,MAHARASHTRA Apple Saraswathi Multispeciality Hospital,MAHARASHTRA Basavatarakam Indoamerican Cancer Hospital and Research Institute,TELANGANA Bharati Hospital,MAHARASHTRA Chopda Medicare & Research Centre Pvt. Ltd,MAHARASHTRA G B Vaghani Multispecialiry Hospital,GUJARAT GBH Memorial Cancer Hospital,RAJASTHAN Global Hospital,GUJARAT Halamma Kerudi cancer Hospital,KARNATAKA HCG CANCER CENTER,ANDHRA PRADESH HCG Cancer Centre,KARNATAKA HCG City Cancer Centre,ANDHRA PRADESH Indrayani Hospital & Cancer institute,MAHARASHTRA Jubilee Mission Hospital,KERALA Justice K S Hegde Charitable Hospital,KARNATAKA Kamalnayan Bajaj Hospital,MAHARASHTRA Kaushalya Medical Foundation Trust Hospital,MAHARASHTRA Kingsway Hospital,MAHARASHTRA Mahatma Gandhi Cancer Hospital & Research Institute,ANDHRA PRADESH Malabar Cancer Centre,KERALA Marathwada Cancer Hospital & Research Institute,MAHARASHTRA MNJ Institute of Oncology & Regional Cancer Center,TELANGANA Mumbai Oncocare Centre,MAHARASHTRA MVR Cancer Centre & Research Institute,KERALA Namco Charitable trusts SSGS Cancer Hospital,MAHARASHTRA Narayana Multispeciality Hospital,GUJARAT Natco Cancer Centre at Government General Hospital,ANDHRA PRADESH Nirmal Hospital PVT LTD,GUJARAT Noble Hospital Pvt Ltd,MAHARASHTRA OncoVille Cancer Hospital and Research Centre,KARNATAKA Rajalakshmi Hospital and Research Center,KARNATAKA Regency Hospital LTD,UTTAR PRADESH Regional Cancer Centre,KERALA Royapettah Government Hospital,TAMIL NADU	View

							<p>Sai Cancer and Research Services Pvt. Ltd., MAHARASHTRA</p> <p>Shalinital Meghe Hospital & Research Centre, MAHARASHTRA</p> <p>Shambhavi Centre for Cancer and Gynaecology, HARKHAND</p> <p>Shankus Hospitals, GUJARAT</p> <p>Shashwat Haemato Onco Associates, GUJARAT</p> <p>Sri Ramachandra Institute of Higher Education and Research, TAMIL NADU</p> <p>Sterling Hospital, GUJARAT</p> <p>Sunshine Global Hospital, GUJARAT</p> <p>Tirunelveli Government Medical college & Hospital, TAMIL NADU</p> <p>Vedant Multispeciality Hospital, MAHARASHTRA</p> <p>VGM Hospital, TAMIL NADU</p> <p>Yenepoya University Medical College Hospital, KARNATAKA</p>	
CTRI/2021/10/037362	HIPPOCAMPAL SPARING RADIOTHERAPY IN LUNG CANCER PATIENTS REQUIRING CRANIAL IRRADIATION	Interventional	Indian: Open to Recruitment	Malignant neoplasms of respiratory and intrathoracic organs	<p>1) Histopathological proven Small Cell Lung Carcinoma.</p> <p>2) Histopathological proven Non Small Cell Lung Carcinoma with BM.</p> <p>3) Patient with BM with more than 5mm from hippocampus on CEMRI Brain</p>	Hippocampal sparing radiotherapy technique in lung cancer patients receiving WBRT for prophylactic or therapeutic purposes	PGIMER, CHANDIGARH	View
CTRI/2022/04/041861	Clinical trial/study for lung cancer patients with ROS1 positive	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1. Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB/C, not amenable for radical treatment) or metastatic (Stage IV) NSCLC that harbors a documented ROS1 gene rearrangement</p> <p>2. No prior treatment with a ROS1 tyrosine kinase inhibitor, chemotherapy, or other systemic therapy for advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC</p>	Entrectinib	<p>All India Institute of Medical Sciences, DELHI</p> <p>Mahamana Pandit Madan Mohan Malaviya Cancer Centre, UTTAR PRADESH</p> <p>Mumbai Oncocare Centre (Unit of Cellcure Cancer Centre Pvt. Ltd.), MAHARASHTRA</p> <p>MVR Cancer Centre & Research Institute, KERALA</p> <p>Tata Medical Center, WEST BENGAL</p>	View
CTRI/2022/02/040116	A Clinical study of Trastuzumab Deruxtecan as first line Treatment for Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of bronchus or lung	<p>1). Histologically documented non-squamous Stage 3 locally advanced and unresectable NSCLC not amenable to treatment with curative intent (surgery or chemoradiotherapy) or Stage 4 or recurrent metastatic NSCLC.</p> <p>2). Participants must be treatment-naïve for palliative intent systemic therapy in locally advanced or metastatic disease and medically fit to receive first-line treatment. Prior local or systemic (neo-adjuvant or adjuvant) treatment for early-stage disease is permitted.</p> <p>3). Documented qualifying HER2 exon 19 or 20 mutation (Appendix O lists qualifying activating HER2 exon 19 or 20 mutations)</p>	Trastuzumab Deruxtecan (T-DXd)	<p>Asian Institute of Gastroenterology Hospitals, TELANGANA</p> <p>HCG Manavata Cancer Centre, MAHARASHTRA</p> <p>Healthcare Global Enterprises Ltd., KARNATAKA</p> <p>Kaklaben Dhirubhai Ambani Hospital and Medical Research Institute MAHARASHTRA</p> <p>Rajiv Gandhi Cancer Institute and Research Centre, DELHI</p> <p>Tata Memorial Hospital, MAHARASHTRA</p>	View
CTRI/2023/03/050253	Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with non-small cell lung cancer.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1) Histologically confirmed locally advanced stage IIIB/IIIC (and not eligible for definitive chemo-radiation curative therapy or complete surgical resection) or stage IV previously treated NSCLC. Presence of a KRAS G12C mutation by central laboratory testing using tissue samples.</p> <p>2) Participants have received one prior platinum-based chemotherapy and one prior immune checkpoint inhibitor therapy either in combination or in sequence.</p>	JDQ443	<p>Basavatarakam Indo American Cancer Hospital & Research Institute, TELANGANA</p> <p>Fortis Hospital Ltd, KARNATAKA</p> <p>HCG Manavata Cancer Centre, MAHARASHTRA</p> <p>Mahatma Gandhi Cancer Hospital & Research Institute, ANDHRA PRADESH</p> <p>Netaji Subhas Chandra Bose Cancer Hospital, WEST BENGAL</p> <p>Rajiv Gandhi Cancer Institute and Research Centre, DELHI</p> <p>Somani Hospital, RAJASTHAN</p> <p>Tata Medical Centre, WEST BENGAL</p> <p>Tata Memorial Hospital, MAHARASHTRA</p>	View
CTRI/2022/06/043460	Study of Durvalumab plus Domvanalimab in Stage III Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Concurrent Chemoradiation Therapy	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1) locally advanced (Stage III), unresectable disease.</p> <p>2) Documented EGFR and ALK wild-type status.</p> <p>3) Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy, which must be completed within 1 to 28 days prior to the first dose of study intervention in the study</p>	Arm A: Durvalumab plus Domvanalimab	<p>Artemis Hospital, HARYANA</p> <p>Bhagwan Mahaveer Cancer Hospital & Research Centre, RAJASTHAN</p> <p>CARE Hospitals, Hyderabad, TELANGANA</p> <p>Cytecare Cancer Hospital, KARNATAKA</p> <p>Dr. B.L Kapur Memorial Hospital, DELHI</p> <p>HealthCare Global Enterprises Limited, KARNATAKA</p> <p>Mahamana Pandit Madan Mohan Malaviya Cancer Centre, UTTAR PRADESH</p> <p>Max Superspeciality Hospital, Mohali, CHANDIGARH</p>	View

							Narayana Superspeciality Hospital, Howrah,WEST BENGAL Rajiv Gandhi Cancer Institute and Research Centre,DELHI Sri Ram Cancer & Super Speciality Centre,RAJASTHAN Tata Medical Centre, Kolkata,WEST BENGAL Thangam Hospital and Thangam Cancer Centre,TAMIL NADU Vardhman Mahavir Medical College & Safdarjung Hospital,DELHI Zydus Cancer Centre,GUJARAT	
CTRI/2022/09/046009	Study of Selpercatinib in Participants with Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) Must have histologically confirmed Stage IB, II, or IIIA NSCLC. 2), Must have an activating RET gene fusion in tumor based on polymerase chain reaction (PCR) or next generation sequencing (NGS).	Selpercatinib	Cancer Relief Society's Rashtra Sant Tukdoji Charitable Cancer Hospital & Research Centre,MAHARASHTRA HCG Manavata Cancer Centre,MAHARASHTRA Rajiv Gandhi Cancer Institute and Research Centre,DELHI Regional Cancer Centre,KERALA Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2022/08/045109	Clinical trial of metformin and valproic acid combination in lung cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of middle lobe,bronchus or lung	Histologically or cytologically confirmed NSCLC, Stage III B or IV planned for palliative intent treatment with pemetrexed + carboplatin. Patients will be enrolled at baseline or within 3 weeks of cycle 1 of chemotherapy.	T.Metformin 1000 mg BD T.Valproate 20 mg/kg/day for 9 weeks in addition to chemotherapy	JIPMER Puducherry,PONDICHERRY	View
CTRI/2023/01/049349	Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of bronchus or lung	1), histologically or cytologically confirmed diagnosis of metastatic NSCLC that carries an ALK rearrangement 2) disease progression after alectinib or certinib as first line therapy	Lorlatinib	Bhaktivedanta Hospital & Research Institute,MAHARASHTRA Healthcare Global Enterprises Limited,KARNATAKA Medanta -The Medicity ,HARYANA Rajiv Gandhi Cancer Institute and Research Centre,DELHI	View
CTRI/2024/01/061436	Study of efficacy and safety of JDQ443 as first-line treatment for patients with locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression 1% or a PD-L1 expression 8%* 1% and an STK11 co-mutation	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	1) Histologically confirmed locally advanced (stage IIIB/IIIC not eligible for definitive chemoradiation or surgical resection with curative intent) or metastatic (stage IV) NSCLC without previous systemic treatment for metastatic disease. Prior (neo)adjuvant treatment with chemotherapy and/or immunotherapy, or prior radiotherapy administered sequentially or concomitantly with chemotherapy and/or immunotherapy for localized or locally advanced disease are accepted if the time between therapy completion and enrollment is > 12 months. 2) Presence of a KRAS G12C mutation (all participants)	JDQ443	Amrita Institute of Medical Sciences,KERALA Caritas Hospital,KERALA JIPMER, Puducherry,TAMIL NADU Mahamana Pandit Madan Mohan Malaviya Cancer Centre,UTTAR PRADESH Tata Medical Centre,WEST BENGAL Tata Memorial Hospital,MAHARASHTRA	View
CTRI/2023/09/057267	Breathing Exercise improve the lung and cardiac functions in lung cancer patients.	Interventional	Indian: Open to Recruitment	Chronic obstructive pulmonary disease with acute lower respiratory infection	3 rd. stage -ECOG Lung Cancer Guidelines Lung Cancer patients under chemotherapy and medication	Diaphragmatic exercises	DR ANIREDDY MULTI SPECIALTY HOSPITALS,ANDHRA PRADESH	View
CTRI/2023/08/056715	A study to evaluate immunotherapy pembrolizumab with chemotherapy in lung cancer patient.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract part unspecified	Subjects must have NSCLC, for adenocarcinoma EGFR, ALK negative mutated and must have been planned for palliative systemic therapy	Paclitaxel (175 mg/m2) with Platinum (Cisplatin- 75 mg/m2 or Carboplatin AUC -5) OR Pemetrexed (500 mg/m2) with Platinum (Cisplatin- 75 mg/m2 or Carboplatin AUC - 5)	All India Institute of Medical Sciences,DELHI Bhagwan Mahaveer Cancer Hospital and Research Centre ,RAJASTHAN HOMI BHABHA CANCER HOSPITAL& RESEARCH CENTRE NEW CHANDIGARH, PUNJAB,CHANDIGARH Oncowin Cancer Center,GUJARAT Tata Memorial Hospital ,MAHARASHTRA	View
CTRI/2024/03/063500	Tislezumab in Combination With Chemotherapy in First-line Treatment of Unresectable/Metastatic Non-small Cell Lung Cancer or Recurrent/Metastatic Squamous Cell Head and Neck Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of bronchus or lung Malignant neoplasm of head, face and neck	Locally advanced or recurrent NSCLC that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic nonsquamous or squamous NSCLC.	Tislezumab	Indur Cancer Hospital,TELANGANA Pi Health Cancer Hospital,TELANGANA	View
CTRI/2024/04/066248	This is a clinical study to compare Dr Reddys developed nivolumab vs. nivolumab originator in patients with Advanced lung cancer who have failed with previous chemotherapy.	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	Patients with histologically- or cytologically-documented squamous cell NSCLC who present with Stage IIIB or Stage IIIC or Stage IV disease, or with recurrence or progressive disease following multimodal therapy Patients with known EGFR, and ALK genomic tumour aberrations should have disease progression on trait specific therapy for these aberrations prior to receiving nivolumab.	DRL_NU (DRL_Nivolumab)	Apollo Hospitals,TAMIL NADU Asirvatham Speciality hospital,TAMIL NADU Aster Medcity ,KERALA Basavatarakam Indo-American Cancer Hospital and Research Institute,TELANGANA Bharath Hospital & Institute of Oncology,KARNATAKA Chittaranjan National Cancer Institute,WEST BENGAL Deenanath Mangeshkar Hospital & Research Center,MAHARASHTRA Erode Cancer Centre Pvt Ltd ,TAMIL NADU Government Medical College,KERALA HCG Cancer Centre,ANDHRA PRADESH HCG City Cancer Centre ,ANDHRA PRADESH	View

							<p>HCG Manavata Cancer Centre ,MAHARASHTRA</p> <p>Jawaharlal Institute of Postgraduate Medical Education & Research(JIPMER),PONDICHERRY</p> <p>Kailash Cancer Hospital and Research Center,GUJARAT</p> <p>KLES Dr. Prabhakar Kore Hospital and MRC ,KARNATAKA</p> <p>Maha mana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH</p> <p>Mahatma Gandhi Cancer Hospital and Research Institute,ANDHRA PRADESH</p> <p>Mangalore Institute of oncology,KARNATAKA</p> <p>Medanta â€œThe Medicity ,HARYANA</p> <p>Meenakshi Mission Hospital and Research Centre,TAMIL NADU</p> <p>MNJ Institute of Oncology and Regional Cancer Centre,TELANGANA</p> <p>MVR Cancer Centre and Research Institute,KERALA</p> <p>Nano Hospitals,KARNATAKA</p> <p>Narayana Multispecialty Hospital,GUJARAT</p> <p>Nizamâ€™s Institute of Medical Sciences (NIMS),TELANGANA</p> <p>Omega Hospitals,ANDHRA PRADESH</p> <p>Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences,HARYANA</p> <p>Pi Health cancer Hospital,TELANGANA</p> <p>R.K.Birla Cancer Centre SMS Medical College and attached hospital ,RAJASTHAN</p> <p>Rabindranath Tagore International institute of cardiac sciences,WEST BENGAL</p> <p>Radhakrishna Multispecialty hospital & IVF Centre,KARNATAKA</p> <p>Rajiv Gandhi Cancer Institute and Research Center,DELHI</p> <p>S.P. Medical College and AG Hospital,RAJASTHAN</p> <p>Sankalp Speciality Hospital,MAHARASHTRA</p> <p>Shalbay hospital,GUJARAT</p> <p>Sparsh Hospital and Critical Care Pvt Ltd ,ORISSA</p> <p>Sujan Surgicals Cancer Hospital and Amravati Cancer foundation,MAHARASHTRA</p> <p>Taran Onco Care (A Unit of Taran Medi Care LLP),MADHYA PRADESH</p> <p>Tata Memorial Hospital,MAHARASHTRA</p> <p>Unique Hospital Multi speciality & Research Institute,GUJARAT</p> <p>V.S. Hospitals,TAMIL NADU</p> <p>Vardhman Mahavir Medical College (VMMC) & Safdarjung Hospital,DELHI</p>	
CTRI/2024/07/07802	First in Human Multicenter Open Name Dose- increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumor	Interventional	Indian: Open to Recruitment	Malignant neoplasm of lower respiratory tract, part unspecified	EGFR Mutated Lung Cancer Patients with or without Brain Metastasis	JBI-778 Oral Capsule 40 mg daily dose in 21-day continuous cycles Once daily dosing in repeated 21-day cycles. JBI-778 capsule is taken orally with water approximately same time either 1 hour before a meal or 2 hours after a meal	<p>All India Institute of Medical Sciences(AIIMS) ,DELHI</p> <p>Artemis Hospital,HARYANA</p> <p>Erode Cancer Centre Private Limited,TAMIL NADU</p> <p>HCG Manavata Cancer Centre,MAHARASHTRA</p> <p>Oncoville Cancer Hospital and Research Center,KARNATAKA</p> <p>Tata Memorial Center,MAHARASHTRA</p>	View
CTRI/2024/12/078579	A study to examine pharmacokinetics, effectiveness, and safety of BAT3306 plus chemotherapy and compare with EU-Keytruda® and US-Keytruda® in participants aged greater than or equal to 18 years with Stage IV non squamous non small cell lung cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1) Histologically/cytologically confirmed diagnosis of Stage IV (AJCC 8th edition) nsNSCLC.</p> <p>2) Tumors without EGFR mutation/ROS1 rearrangement /ALK rearrangement.</p>	BAT3306, EU-Keytruda®, and US-Keytruda®	<p>Cancer Relief Societyâ€™s RST Regional Cancer Hospital and Research Centre,MAHARASHTRA</p> <p>Chittaranjan National Cancer Institute ,WEST BENGAL</p> <p>Chopada Medicare and research centre Pvt Ltd,MAHARASHTRA</p> <p>Dr. Ram Manohar Lohia Institute of Medical Sciences,UTTAR PRADESH</p> <p>GBH memorial cancer hospital,RAJASTHAN</p> <p>HCG Manavata Cancer Centre,MAHARASHTRA</p> <p>Hemato Oncology Clinic Ahmedabad Pvt Ltd,GUJARAT</p> <p>K R. Hospital ,KARNATAKA</p>	View

							<p>KIMS- Kingsway Hospitals, SPANV Medisearch Lifesciences Private Limited,MAHARASHTRA</p> <p>Narayan Multispecialty Hospital (Unit of Narayan Hrudayalaya Limited),GUJARAT</p> <p>National Cancer Institute,MAHARASHTRA</p> <p>Nirmal Hospital Pvt Ltd,GUJARAT</p> <p>Regional cancer centre,KERALA</p> <p>Sparsh Hospitals & Critical Care Private limited,ORISSA</p> <p>State Cancer Institute, Indira Gandhi Institute of Medical Science,BIHAR</p> <p>Tata Memorial hospital,MAHARASHTRA</p>	
CTRI/2023/05/052218	Study of Datopotamab Deruxtecan (Dato-DXd) for first line treatment of patients with locally advanced or metastatic NSCLC	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>a) Is Stage IIIB or IIIC disease not amenable for surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC disease at the time of randomisation who have not received prior chemotherapy or other systemic therapy for first-line Stage IIIB, IIIC or IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to IIIA) are eligible, provided that progression has occurred 6 months from the last dose of checkpoint inhibitor, chemotherapy, or other systemic anti-cancer therapy.</p> <p>b) Lacks sensitising EGFR tumour tissue mutation (eg, exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation), as well as ALK and ROS1 rearrangements.</p> <p>c) Has no documented tumour genomic alteration results in NTRK, BRAF, RET, MET or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.</p>	Datopotamab Deruxtecan Durvalumab Carboplatin	<p>All India Institute of Medical Sciences,DELHI</p> <p>Bhagwan Mahaveer Hospital and Research Centre,RAJASTHAN</p> <p>Jawaharlal Institute of Postgraduate Medical Education & Research,PONDICHERRY</p> <p>Meenakshi Mission Hospital and Research Centre,TAMIL NADU</p> <p>MVR Cancer Hospital & Research Institute,KERALA</p> <p>Rajiv Gandhi Cancer Institute and Research Centre,DELHI</p> <p>Tata Medical Center, Kolkata,WEST BENGAL</p>	View
CTRI/2024/10/075387	A Global Study of Volrustomig (MED15752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>Histologically or cytologically documented squamous or non-squamous NSCLC. Stage IV NSCLC not amenable to curative surgery or radiation. Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations) and ALK and ROS1 rearrangements.</p>	Experimental Arm-1 Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via IV infusion	<p>Bharat Hospital and Institute of Oncology,KARNATAKA</p> <p>CARE Hospitals,TELANGANA</p> <p>HCG Manavata Cancer Centre ,MAHARASHTRA</p> <p>KIMS - KINGSWAY HOSPITALS,MAHARASHTRA</p> <p>Mahamana Pandit Madan Mohan Malviya Cancer Centre,UTTAR PRADESH</p> <p>Netaji Subhas Chandra Bose Cancer Hospital,WEST BENGAL</p> <p>NH-Rabindranath Tagore International Institute of Cardiac Sciences WEST BENGAL</p> <p>Radhakrishna Multispecialty Hospital,KARNATAKA</p> <p>Rajiv Gandhi Cancer Institute and Research Centre,DELHI</p> <p>Vardham Mahavir Medical College and Safdarjung Hospital,DELHI</p>	View
CTRI/2024/10/075224	A study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor ROS1 positive Non-Small Cell Lung Cancer	Interventional	Indian: Open to Recruitment	Malignant neoplasm of unspecified part of bronchus or lung	<p>1) Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC (eg, crizotinib, ceritinib, lorlatinib, brigatinib, entrectinib, ensartinib, DS605 1 b, NVL-520, taletrectinib, foretinib, and cabozantinib)</p> <p>2) Participant has a ROS1 gene rearrangement or fusion as detected by a local test.</p> <p>3) confirmed diagnosis of locally advanced or metastatic NSCLC</p>	Repotrectinib 40mg,160-mg capsules	<p>All India Institutes of Medical Sciences,DELHI</p> <p>Artemis Hospital,HARYANA</p> <p>Fortis Memorial Research Institute,HARYANA</p> <p>HCG Cancer Centre,GUJARAT</p> <p>Hemato Oncology Clinic Ahmedabad Pvt Ltd,GUJARAT</p> <p>Manipal Hospitals,KARNATAKA</p> <p>Nizams Institute of Medical Sciences,TELANGANA</p> <p>Rajiv Gandhi Cancer Institute & Research Centre,DELHI</p> <p>Regional Cancer Centre hospital ,KERALA</p> <p>Ruby Hall Clinic,MAHARASHTRA</p> <p>Sahyadri Super Speciality Hospital,MAHARASHTRA</p> <p>Sir H. N. Reliance Foundation Hospital and Research Centre,MAHARASHTRA</p> <p>Tata Memorial Centre,MAHARASHTRA</p>	View

	<p>A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression $\geq 50\%$ or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.</p>	Interventional	Indian: Open to Recruitment	Non small Cell Lung Cancer		LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab	Rajiv Gandhi cancer institute and research centre (Dr Ulhas Batra)	
--	---	----------------	-----------------------------	----------------------------	--	--	--	--